Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
Published on 5/3/2026
AI Summary
Pfizer (PFE) stock is down over 50% from its 2021 high as demand for COVID vaccines decreases. The company is facing headwinds, including upcoming patent cliffs that could lead to revenue declines for key drugs. Despite this, Pfizer maintains a 6.4% dividend yield, with management stating that supporting the dividend is a key corporate goal. The company has taken steps to pivot towards GLP-1 weight-loss drugs and continues to develop its portfolio in oncology and migraine treatments, which could improve its market position in the future.
Related News
Earnings
SLRC Maintains Dividend Amid Rate Pressure with 10.5% Yield
May 3
Regulation
Supreme Court petition on mifepristone mail-order access impacts market
May 3
Earnings
Pfizer (PFE) Receives FDA Approval for Veppanu Breast Cancer Drug
May 2
Earnings
Vivakor (VIVK) Resets Special Dividend Payment Date to June 30
Apr 30